Elevai Labs (ELAB) Competitors

Cellectar Biosciences (NASDAQ:CLRB) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, community ranking, analyst recommendations, dividends, earnings, media sentiment and risk.

Is CLRB or ELAB more profitable?

Cellectar Biosciences has a net margin of 0.00% compared to Elevai Labs' net margin of -223.41%. Cellectar Biosciences' return on equity of 0.00% beat Elevai Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	N/A	-191.22%
Elevai Labs	-223.41%	-124.93%	-85.10%

Do insiders and institutionals have more ownership in CLRB or ELAB?

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 22.2% of Elevai Labs shares are owned by institutional investors. 5.0% of Cellectar Biosciences shares are owned by insiders. Comparatively, 0.6% of Elevai Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the MarketBeat Community believe in CLRB or ELAB?

Cellectar Biosciences received 243 more outperform votes than Elevai Labs when rated by MarketBeat users. Likewise, 53.29% of users gave Cellectar Biosciences an outperform vote while only 0.00% of users gave Elevai Labs an outperform vote.

Company	Underperform	Outperform
Cellectar Biosciences	Outperform Votes 243 53.29%	Underperform Votes 213 46.71%
Elevai Labs	Outperform Votes No Votes	Underperform Votes 1 100.00%

Which has higher valuation and earnings, CLRB or ELAB?

Elevai Labs has higher revenue and earnings than Cellectar Biosciences. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Elevai Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$42.77M	-$0.73	-0.58
Elevai Labs	$2.45M	1.23	-$4.30M	-$433.87	-0.01

Which has more volatility & risk, CLRB or ELAB?

Cellectar Biosciences has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Elevai Labs has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500.

Does the media refer more to CLRB or ELAB?

In the previous week, Cellectar Biosciences had 3 more articles in the media than Elevai Labs. MarketBeat recorded 5 mentions for Cellectar Biosciences and 2 mentions for Elevai Labs. Elevai Labs' average media sentiment score of 0.93 beat Cellectar Biosciences' score of 0.48 indicating that Elevai Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elevai Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate CLRB or ELAB?

Cellectar Biosciences presently has a consensus price target of $12.50, indicating a potential upside of 2,828.77%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Cellectar Biosciences is more favorable than Elevai Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Elevai Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Cellectar Biosciences beats Elevai Labs on 11 of the 17 factors compared between the two stocks.